Pregnancies and live births after trophectoderm biopsy and preimplantation genetic testing of human blastocysts

2005 ◽  
Vol 84 (6) ◽  
pp. 1628-1636 ◽  
Author(s):  
Steven J. McArthur ◽  
Don Leigh ◽  
James T. Marshall ◽  
Kylie A. de Boer ◽  
Robert P.S. Jansen
Zygote ◽  
2018 ◽  
Vol 26 (3) ◽  
pp. 191-198 ◽  
Author(s):  
Lluc Coll ◽  
Mònica Parriego ◽  
Montserrat Boada ◽  
Marta Devesa ◽  
Gemma Arroyo ◽  
...  

SummaryShortly after the implementation of comprehensive chromosome screening (CCS) techniques for preimplantation genetic testing for aneuploidies (PGT-A), the discussion about the transition from day 3 to blastocyst stage biopsy was initiated. Trophectoderm biopsy with CCS is meant to overcome the limitations of cleavage-stage biopsy and single-cell analysis. The aim of this study was to assess the results obtained in our PGT-A programme after the implementation of this new strategy. Comparisons between the results obtained in 179 PGT-A cycles with day 3 biopsy (D+3) and fresh embryo transfer, and 204 cycles with trophectoderm biopsy and deferred (frozen–thawed) embryo transfer were established. Fewer embryos were biopsied and a higher euploidy rate was observed in the trophectoderm biopsy group. No differences in implantation (50.3% vs. 61.4%) and clinical pregnancy rate per transfer (56.1% vs. 65.3%) were found. Although the mean number of euploid embryos per cycle did not differ between groups (1.5 ± 1.7 vs. 1.7 ± 1.8), the final number of euploid blastocysts available for transfer per cycle was significantly higher in the trophectoderm biopsy group (1.1 ± 1.3 vs. 1.7 ± 1.8). This factor led to an increased cumulative live birth rate in this last group (34.1% vs. 44.6%). Although both strategies can offer good results, trophectoderm biopsy offers a more robust diagnosis and the intervention is less harmful for the embryos so more euploid blastocysts are finally available for transfer and/or vitrification.


2020 ◽  
Vol 37 (9) ◽  
pp. 2305-2313
Author(s):  
Chun-I Lee ◽  
En-Hui Cheng ◽  
Maw-Sheng Lee ◽  
Pin-Yao Lin ◽  
Yi-Chun Chen ◽  
...  

2020 ◽  
Vol 26 (4) ◽  
pp. 269-276 ◽  
Author(s):  
Rostislav Navratil ◽  
Jakub Horak ◽  
Miroslav Hornak ◽  
David Kubicek ◽  
Maria Balcova ◽  
...  

Abstract Chromosomal mosaicism detected during preimplantation genetic testing for aneuploidy (PGT-A) and its impact on embryo implantation have been widely discussed, and healthy live births from mosaic embryos were reported by many groups. On the other hand, only very few studies have focused on segmental chromosome aneuploidies and their clinical impact. Eighty-nine embryos with various PGT-A results (trophectoderm 1: TE1) were re-analysed using a second trophectoderm biopsy (TE2) and the rest of the embryo (RE) for testing. Of 19 euploid TE1 biopsies, 18 were concordant across TE2 and RE. Similarly, whole chromosomal aneuploidies were concordant in 59 of 62 TE1-TE2 and 58 TE1-RE. In contrast, from 31 segmental aneuploidies detected in TE1, only 15 were observed again in TE2 and 14 in RE. If a TE1 segmental abnormality appeared again in TE2, it was almost always present in RE (17/18) as well. Moreover, when a TE1 segmental abnormality was not detected in TE2, in 12 out of 13 cases RE was also unaffected. Similarly, only 1 of 26 TE1 whole chromosome mosaics were repeated in TE2 and 7 in RE. Our study confirms that euploid and whole chromosomal aneuploidy results are highly predictive of the embryo. In contrast, mosaicism has a very low concordance rate. Most importantly, re-biopsy of embryos with segmental aneuploidies demonstrated that they are mostly not uniform across the embryo. Finally, in the case of segmental aneuploidy, the second biopsy enables an accurate prediction of the real status of the embryo and could be offered to patients undergoing PGT-A.


Sign in / Sign up

Export Citation Format

Share Document